MedTrace Logo

Cordimax China Post Market Surveillance

NCT03185221 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3660

Last updated 2017-06-14

No results posted yet for this study

Summary

Study purpose: This study is a prospective, randomized, controlled multicenter clinical research, which is to assess the effect of Cordimax and Xience V drug-eluting stents as they dealing with all kinds of complex lesions in the real world.

Study group Experimental group: Cordimax® Rapamycin Eluting Coronary Stent System Control group: XIENCE V® Everolimus Eluting Coronary Stent System

Conditions

  • Coronary Artery Stenosis

Interventions

DEVICE

Cordimax

One rapamycin eluting stent for treating the adapted coronary patients

DEVICE

XIENCE V

One everolimus eluting stent for treating the adapted coronary patients

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Shandong Branden Med.Device Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Junbo Ge · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-20
Primary Completion
2019-06-20
Completion
2020-06-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03185221 on ClinicalTrials.gov